Rat Cannabinoid Receptor 2, Macrophage (CNR2) CLIA Kit

Product specifications

CLIA Kits

Cannabinoid Receptor 2, Macrophage (CNR2)

Rat

Chemiluminescent

Quantitative

Sandwich

0.156 ng/ml - 10 ng/ml

< 0.059 ng/ml

Optimal dilutions/concentrations should be determined by the end user.

96 tests

5 × 96 tests

10 × 96 tests

Lyophilized

CLIA

Tissue homogenates, cell lysates and other biological fluids.

Shipped within 5-20 working days.

Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

No

CNR2,Rcb2,cannabinoid receptor 2,CB2-R,Peripheral cannabinoid receptor, CB-2, CB2, CX5,Cannabinoid Receptor 2 Macrophage

CLIA Kits CNR2

RUO

The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request.   This product is for research use only.   The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.   Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Descripción

Cannabinoid Receptor 2 (CNR2), also known as CB2, is the second major receptor of the endocannabinoid system (ECS) and is predominantly expressed in immune cells, including macrophages, B-cells, T-cells, and microglia. Unlike CB1, CB2 is primarily located in the peripheral nervous system (PNS) and immune system, where it modulates inflammation, immune response, and tissue repair. Activation of CB2 by endocannabinoids like 2-AG or synthetic cannabinoids suppresses pro-inflammatory cytokine release, attenuating inflammatory responses and providing protection against autoimmune diseases and chronic inflammatory conditions such as rheumatoid arthritis and multiple sclerosis. CB2 also plays a critical role in regulating neuroinflammation and protecting neurons in neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and Huntington's disease by reducing oxidative stress and apoptosis. Additionally, CB2 is expressed in tissues like the liver, lungs, and bone, where it regulates processes like fibrosis, wound healing, and bone remodeling, highlighting its importance in diseases like liver fibrosis and osteoporosis. CB2 receptors are not associated with psychoactive effects, making them a promising therapeutic target for chronic pain, neuropathic pain, and cancer. CB2 agonists are actively being developed for clinical applications, particularly in inflammation, immune modulation, and cancer therapy, where CB2 activation can suppress tumor growth and metastasis. Ongoing research into CB2 biology underscores its potential as a non-psychoactive therapeutic target for a wide range of inflammatory, neurodegenerative, and immune-related disorders.

Related Products

Mouse CNR2 (Cannabinoid Receptor 2) ELISA Kit

Ver Producto

Cannabinoid Receptor 2 (CB2) Antibody

The cannabinoid delta-9-tetrahydrocannabinol is the principal psychoactive ingredient of marijuana. The proteins encoded by this gene and the cannabinoid receptor 1 (brain) (CNR1) gene have the characteristics of a guanine nucleotide-binding protein (G-protein) coupled receptor for cannabinoids. They inhibit adenylate cyclase activity in a dose-dependent, stereoselective, and pertussis toxin-sensitive manner. These proteins have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. The cannabinoid receptors are members of family 1 of the G-protein-coupled receptors.

Ver Producto

Cannabinoid Receptor 2 (CNR2) Antibody

Rabbit Polyclonal against the Cannabinoid receptor 2 protein.

Ver Producto